"5" . . . "Bravencov\u00E1, Zlatu\u0161e" . . "V\u00FDchodiska: Metastatick\u00FD karcinom prsu je nevyl\u00E9\u010Diteln\u00E9 onemocn\u011Bn\u00ED, c\u00EDlem l\u00E9\u010Dby je prodlou\u017Een\u00ED \u017Eivota pacientky p\u0159i zachov\u00E1n\u00ED \u010Di zlep\u0161en\u00ED jeho kvality. T\u0159i studie f\u00E1ze III (E2100, AVADO a RIBBON-1) prok\u00E1zaly p\u0159\u00EDnos p\u0159id\u00E1n\u00ED bevacizumabu ke standardn\u00ED chemoterapii 1. linie. V t\u011Bchto studi\u00EDch bylo dosa\u017Eeno zv\u00FD\u0161en\u00ED \u010Detnosti odpov\u011Bd\u00ED a prodlou\u017Een\u00ED p\u0159e\u017Eit\u00ED bez progrese. P\u0159id\u00E1n\u00ED bevacizumabu nezvy\u0161uje toxicitu chemoterapeutick\u00FDch re\u017Eim\u016F. Bevacizumab je od roku 2007 registrov\u00E1n k l\u00E9\u010Db\u011B nemocn\u00FDch s metastazuj\u00EDc\u00EDm karcinomem prsu. P\u0159\u00EDpad: Uv\u00E1d\u00EDme kazuistiku na\u0161\u00ED pacientky l\u00E9\u010Den\u00E9 bevacizumabem, u kter\u00E9 bylo dosa\u017Eeno v\u00FDborn\u00E9ho l\u00E9\u010Debn\u00E9ho efektu. V roce 2003 byl u tehdy 40let\u00E9 pacientky diagnostikov\u00E1n lobul\u00E1rn\u00ED karcinom prsu pT2pN0M0, ER negativn\u00ED, PgR negativn\u00ED, HER2 negativn\u00ED. Byla pod\u00E1na adjuvantn\u00ED chemoterapie FAC. Po \u0161esti letech, v b\u0159eznu 2009, do\u0161lo k relapsu onemocn\u011Bn\u00ED s posti\u017Een\u00EDm mediastin\u00E1ln\u00EDch uzlin, plic, pleury a skeletu. V kv\u011Btnu 2009 byla zah\u00E1jena l\u00E9\u010Dba t\u00FDdenn\u00EDm re\u017Eimem paklitaxelu (ukon\u010Den v listopadu 2009) v kombinaci s bevacizumabem, kter\u00FD byl ukon\u010Den v dubnu 2010 po 11 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby p\u0159i dosa\u017Een\u00ED \u00FApln\u00E9 remise, a to jak v plic\u00EDch a mediastinu, tak ve skeletu. L\u00E9\u010Dba pokra\u010Duje pouze pod\u00E1v\u00E1n\u00EDm bisfosfon\u00E1tu. Z\u00E1v\u011Br: I na\u0161e zku\u0161enost ukazuje, \u017Ee bevacizumab je p\u0159\u00EDnosem pro l\u00E9\u010Dbu metastatick\u00E9ho karcinomu prsu." . "RIV/00843989:_____/10:00103141" . "Kazuistika pacientky s triple negativn\u00EDm karcinomem prsu, kter\u00E1 p\u0159i l\u00E9\u010Db\u011B paklitaxelem a bevacizumabem dos\u00E1hla kompletn\u00ED remise plicn\u00EDho, uzlinov\u00E9ho a kostn\u00EDho metastatick\u00E9ho posti\u017Een\u00ED" . "CZ - \u010Cesk\u00E1 republika" . "0862-495X" . "A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab"@en . "3"^^ . . "[880E694F2E36]" . . . "23" . . "Kazuistika pacientky s triple negativn\u00EDm karcinomem prsu, kter\u00E1 p\u0159i l\u00E9\u010Db\u011B paklitaxelem a bevacizumabem dos\u00E1hla kompletn\u00ED remise plicn\u00EDho, uzlinov\u00E9ho a kostn\u00EDho metastatick\u00E9ho posti\u017Een\u00ED"@cs . "RIV/00843989:_____/10:00103141!RIV13-MZ0-00843989" . . "V" . "266261" . . "A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab"@en . . . "1"^^ . . "Backgrounds: Metastatic breast cancer is a disease which is not curable. Thus, prolongation of survival with preserved or improved quality of life is the aim of the treatment. Three phase III studies (E2100, AVADO and RIBBON-1) showed the benefit of adding bevacizumab to the standard 1st line chemotherapy. Higher response rate and longer progression-free survival were achieved in these studies. Bevacizumab does not increase toxicity of the chemotherapy regimens. Since 2007 bevacizumab has been registered for the treatment of patients with metastatic breast cancer. Observation: Here we present the case of a patient in which bevacizumab treatment led to excellent results. Lobular breast cancer, pT2N0M0, ER-negative, PR-negative, HER2-negative was diagnosed in a 40-year-old woman in 2003. FAC adjuvant chemotherapy was used. Six years later, in March 2009, a relapse in mediastinal lymphatic nodes, the lungs, pleura and bones was detected. A weekly regimen of paclitaxel in combination with bevacizumab started in May 2009. Paclitaxel treatment finished in November 2009, bevacizumab continued for 11 months till April 2010, when complete remission in the lungs, mediastinum and bones was confirmed. Now only bisphosphonate is being continued. Conclusion: our experience also confirms the contribution of bevacizumab in the treatment of metastatic breast cancer."@en . "metastatic breast cancer; paclitaxel; bevacizumab"@en . "Kazuistika pacientky s triple negativn\u00EDm karcinomem prsu, kter\u00E1 p\u0159i l\u00E9\u010Db\u011B paklitaxelem a bevacizumabem dos\u00E1hla kompletn\u00ED remise plicn\u00EDho, uzlinov\u00E9ho a kostn\u00EDho metastatick\u00E9ho posti\u017Een\u00ED"@cs . "V\u00FDchodiska: Metastatick\u00FD karcinom prsu je nevyl\u00E9\u010Diteln\u00E9 onemocn\u011Bn\u00ED, c\u00EDlem l\u00E9\u010Dby je prodlou\u017Een\u00ED \u017Eivota pacientky p\u0159i zachov\u00E1n\u00ED \u010Di zlep\u0161en\u00ED jeho kvality. T\u0159i studie f\u00E1ze III (E2100, AVADO a RIBBON-1) prok\u00E1zaly p\u0159\u00EDnos p\u0159id\u00E1n\u00ED bevacizumabu ke standardn\u00ED chemoterapii 1. linie. V t\u011Bchto studi\u00EDch bylo dosa\u017Eeno zv\u00FD\u0161en\u00ED \u010Detnosti odpov\u011Bd\u00ED a prodlou\u017Een\u00ED p\u0159e\u017Eit\u00ED bez progrese. P\u0159id\u00E1n\u00ED bevacizumabu nezvy\u0161uje toxicitu chemoterapeutick\u00FDch re\u017Eim\u016F. Bevacizumab je od roku 2007 registrov\u00E1n k l\u00E9\u010Db\u011B nemocn\u00FDch s metastazuj\u00EDc\u00EDm karcinomem prsu. P\u0159\u00EDpad: Uv\u00E1d\u00EDme kazuistiku na\u0161\u00ED pacientky l\u00E9\u010Den\u00E9 bevacizumabem, u kter\u00E9 bylo dosa\u017Eeno v\u00FDborn\u00E9ho l\u00E9\u010Debn\u00E9ho efektu. V roce 2003 byl u tehdy 40let\u00E9 pacientky diagnostikov\u00E1n lobul\u00E1rn\u00ED karcinom prsu pT2pN0M0, ER negativn\u00ED, PgR negativn\u00ED, HER2 negativn\u00ED. Byla pod\u00E1na adjuvantn\u00ED chemoterapie FAC. Po \u0161esti letech, v b\u0159eznu 2009, do\u0161lo k relapsu onemocn\u011Bn\u00ED s posti\u017Een\u00EDm mediastin\u00E1ln\u00EDch uzlin, plic, pleury a skeletu. V kv\u011Btnu 2009 byla zah\u00E1jena l\u00E9\u010Dba t\u00FDdenn\u00EDm re\u017Eimem paklitaxelu (ukon\u010Den v listopadu 2009) v kombinaci s bevacizumabem, kter\u00FD byl ukon\u010Den v dubnu 2010 po 11 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby p\u0159i dosa\u017Een\u00ED \u00FApln\u00E9 remise, a to jak v plic\u00EDch a mediastinu, tak ve skeletu. L\u00E9\u010Dba pokra\u010Duje pouze pod\u00E1v\u00E1n\u00EDm bisfosfon\u00E1tu. Z\u00E1v\u011Br: I na\u0161e zku\u0161enost ukazuje, \u017Ee bevacizumab je p\u0159\u00EDnosem pro l\u00E9\u010Dbu metastatick\u00E9ho karcinomu prsu."@cs . "Kazuistika pacientky s triple negativn\u00EDm karcinomem prsu, kter\u00E1 p\u0159i l\u00E9\u010Db\u011B paklitaxelem a bevacizumabem dos\u00E1hla kompletn\u00ED remise plicn\u00EDho, uzlinov\u00E9ho a kostn\u00EDho metastatick\u00E9ho posti\u017Een\u00ED" . "1"^^ . . "Klinick\u00E1 onkologie" . .